Table A6

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†

, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†

Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Cost-benefit ratios when applying combinations of model parameters in a sensitivity analysis

Probability of pandemic	Estimates of health-related pandemic outcomes*
	Minimum			Base case			Maximum
	1/100 y	1/33 y	1/10 y	1/100 y	1/33 y	1/10 y	1/100 y	1/33 y	1/10 y
Strategy
Therapeutic use
All patients	0.71–0.79	2.13–2.37	7.10–7.92	0.73–0.87	2.18–2.62	7.25–8.74	0.74–0.96	2.23–2.88	7.42–9.61
Patients at high risk	0.80–1.21	2.40–3.63	7.99–12.09	0.84–1.50	2.51–4.49	8.36–14.96	0.88–1.74	2.63–5.23	8.76–17.42
Preexposure long-term prophylaxis
Entire population	0.04–0.11	0.13–0.34	0.42–1.13	0.07–0.19	0.21–0.58	0.71–1.92	0.10–0.28	0.30–0.83	1.00–2.76
Patients at high risk	0.04–0.10	0.11–0.30	0.38–1.02	0.07–0.18	0.20–0.55	0.67–1.85	0.10–0.28	0.30–0.83	0.99–2.77
Postexposure short-term prophylaxis	0.18–1.14	0.54–3.42	1.82–11.40	0.30–1.94	0.91–5.81	3.04–19.37	0.43–2.78	1.30–8.35	4.32–27.83

*Base-case estimates refer to the point estimates detailed in Table A1. Minimum and maximum estimates refer to applying minimum and maximum values of health-related outcome measures detailed in Table A1.

Main Article

Page created: April 23, 2012

Page updated: April 23, 2012

Page reviewed: April 23, 2012

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Volume 11, Number 8—August 2005

Dispatch

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Table A6